News

3-year REMAIN data show MCO-010 optogenetic therapy delivered durable ~3-line vision gains in retinitis pigmentosa regardless of gene mutation, with no treatment-related serious adverse events, per Benjamin Bakall, MD, PhD, at ASRS 2026.

AI-driven OCT analysis shows faricimab reduces diabetic macular edema fluid and thickness more than aflibercept, suggesting eccentric subfields may guide treat-and-extend dosing.

Creators on TikTok and YouTube share real LASIK journeys, bust myths, and help Gen Z and millennials explore modern vision correction options.

Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.

Building judgment and adaptability to navigate AI, gene therapy, and constant change.

ARCHER data reveal which GA eyes risk major vision loss: midrange baseline acuity and subfoveal lesions, shaping counseling and future AMD trials.

A 10-year analysis finds latanoprost accounts for 40% of glaucoma prescriptions in New Zealand.

A real-world Vestrum database analysis found pegcetacoplan was linked to better visual acuity outcomes in geographic atrophy, including in patients with concurrent neovascular AMD, per Nimesh Patel, MD, at ASRS 2026.

Michael Ip, MD, presented a large-scale analysis of OCT biomarkers in diabetic macular edema (DME), drawing on data from the DRCR Retina Network's Protocol T trial.

An AI platform that screens patient charts for clinical trial eligibility increased randomization by 37.5% and cut screen failures by 13% in a retina practice.

Arshad M. Khanani, MD, MA, discusses phase 3 SOL-1 data showing axitinib sustained vision in wet AMD for 9-12 months after 1 dose, outperforming aflibercept 2 mg.

Applying phase 3 LUGANO/LUCIA criteria to the phase 2 DAVIO 2 population showed stable vision and anatomy with the vorolanib insert EYP-1901 in wet AMD, Aleksandra Rachitskaya, MD, FASRS, reported at ASRS 2026.

Rare retinal diseases initially were the primary targets of gene therapy, but that is no longer the case. The focus has expanded beyond those to also include more common, chronic diseases such as diabetic macular edema and wet age-related macular degeneration. During the first half of 2026, that trend was evident.

The multicenter study is evaluating ZOC2017217, a lanosterol-derived investigational eye drop, ahead of a planned phase 3 trial.

Rising star in Ophthalmology, Nicholas Riina, MS, focuses on artificial intelligence and uses robotics training to enhance glaucoma diagnosis.

OLN324 outperformed faricimab on anatomic outcomes as early as week 1 in the JADE trial, with no cases of intraocular inflammation across both dose groups.

The randomized, double-masked, 3-arm trial did not achieve its primary endpoint of replicating the visual function improvements observed in a smaller phase 1/2a study.

Initiating aflibercept 8 mg or faricimab as a first-line therapy was associated with longer treatment intervals and superior anatomic outcomes in a real-world analysis of more than 12,000 eyes.

In the latest episode of The Retina TL;DR with Dr. Weng, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Brodie about a photovoltaic subretinal implant showing meaningful visual gains in patients with geographic atrophy due to AMD.

Cynthia Toth, MD, of Duke University, discusses new BabySTEPS research showing that retinal nerve fiber layer and choroidal thickness on OCT correlate with 2-year neurodevelopmental outcomes in preterm infants and what it will take to bring bedside screening into routine NICU care.

Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,

The long-term outcomes after primary scleral buckling procedures for rhegmatogenous retinal detachments showed high anatomic success, improved vision, and a good safety profile.

A new survey has discovered a gap between the value parents place on children's vision and the comprehensive eye care that teens and young adults receive.

A recap of the FDA approvals, phase 3 readouts, and pipeline data that shaped diabetic eye disease care in the first half of 2026.

Esen Akpek, MD, on dry eye's emotional and vision-related toll, its hidden autoimmune links, and when to move patients beyond artificial tears.

The non-exclusive license agreement pairs Alcon's PCIOL optical designs with RxSight's post-operative light-adjustable platform, with the aim of allowing surgeons to fine-tune visual outcomes after cataract surgery.

Antineoplastics were the most frequently implicated drug class in review

Cascade Prodrug and Uneedle are partnering to test suprachoroidal delivery of CPD100 using Uneedle's Bella-Vue microneedle system for the treatment of wet AMD.